Cargando…
JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition
A recent article published by Britschgi et al. in Cancer Cell, “JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer,” describes a positive feedback loop of JAK2/STAT5 activation that drives resistance to PI3K/mTOR...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891630/ https://www.ncbi.nlm.nih.gov/pubmed/24470973 http://dx.doi.org/10.4161/jkst.24635 |
_version_ | 1782299408253059072 |
---|---|
author | Yeh, Jennifer E Toniolo, Patricia A Frank, David A |
author_facet | Yeh, Jennifer E Toniolo, Patricia A Frank, David A |
author_sort | Yeh, Jennifer E |
collection | PubMed |
description | A recent article published by Britschgi et al. in Cancer Cell, “JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer,” describes a positive feedback loop of JAK2/STAT5 activation that drives resistance to PI3K/mTOR inhibition in breast cancer. The authors found that genetic or pharmacological inhibition of JAK2 circumvents resistance to PI3K/mTOR inhibition and go on to show the efficacy of combined PI3K/mTOR and JAK2 inhibition on reducing cancer cell number, tumor growth, and metastasis as well as increasing in vivo survival. These results provide strong support for combination therapy with JAK2/STAT5 and PI3K/mTOR inhibitors in breast cancer. Here we discuss how the article by Britschgi et al. proposes a novel mechanism to explain how breast cancer cells overcome inhibition of a key signaling pathway driving cell proliferation. We also discuss the interplay between activation of the transcription factors STAT5 and STAT3 in breast cancer. |
format | Online Article Text |
id | pubmed-3891630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-38916302014-01-27 JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition Yeh, Jennifer E Toniolo, Patricia A Frank, David A JAKSTAT Commentary A recent article published by Britschgi et al. in Cancer Cell, “JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer,” describes a positive feedback loop of JAK2/STAT5 activation that drives resistance to PI3K/mTOR inhibition in breast cancer. The authors found that genetic or pharmacological inhibition of JAK2 circumvents resistance to PI3K/mTOR inhibition and go on to show the efficacy of combined PI3K/mTOR and JAK2 inhibition on reducing cancer cell number, tumor growth, and metastasis as well as increasing in vivo survival. These results provide strong support for combination therapy with JAK2/STAT5 and PI3K/mTOR inhibitors in breast cancer. Here we discuss how the article by Britschgi et al. proposes a novel mechanism to explain how breast cancer cells overcome inhibition of a key signaling pathway driving cell proliferation. We also discuss the interplay between activation of the transcription factors STAT5 and STAT3 in breast cancer. Landes Bioscience 2013-10-01 2013-04-15 /pmc/articles/PMC3891630/ /pubmed/24470973 http://dx.doi.org/10.4161/jkst.24635 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Commentary Yeh, Jennifer E Toniolo, Patricia A Frank, David A JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition |
title | JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition |
title_full | JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition |
title_fullStr | JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition |
title_full_unstemmed | JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition |
title_short | JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition |
title_sort | jak2-stat5 signaling: a novel mechanism of resistance to targeted pi3k/mtor inhibition |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891630/ https://www.ncbi.nlm.nih.gov/pubmed/24470973 http://dx.doi.org/10.4161/jkst.24635 |
work_keys_str_mv | AT yehjennifere jak2stat5signalinganovelmechanismofresistancetotargetedpi3kmtorinhibition AT toniolopatriciaa jak2stat5signalinganovelmechanismofresistancetotargetedpi3kmtorinhibition AT frankdavida jak2stat5signalinganovelmechanismofresistancetotargetedpi3kmtorinhibition |